Dynavax Technologies Corporation (DVAX)
US$ 13.79-4.17%
Price Chart
Key Statistics
Market Cap
$ 1.16B
P/E Ratio
0.00
Revenue (TTM)
$ 294.62M
Volume
3.45M
52W High
$ 14.63
52W Low
$ 9.22
Dividend Yield
0.00%
Beta
1.26
Technicals
50-Day MA
12.0478
200-Day MA
12.0415
52 Week High
14.63
52 Week Low
9.22
About DVAX
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV.
Employees
405
Headquarters
EmeryVille, CA
CEO
Mr. Ryan Spencer
Latest News
Dynavax Files Preliminary Proxy Statement - PR Newswire
2025-04-03 • Google News
Dynavax Technologies (DVAX) Upgraded to Buy: Here's Why - Yahoo Finance
2 weeks ago • Google News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg